Edition:
India

VistaGen Therapeutics Inc (VTGN.OQ)

VTGN.OQ on NASDAQ Stock Exchange Capital Market

1.17USD
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
$1.17
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
162,639
52-wk High
$3.91
52-wk Low
$0.69

Chart for

About

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II... (more)
No analyst recommendations are available for .

Overall

Beta: -0.57
Market Cap(Mil.): $17.09
Shares Outstanding(Mil.): 10.75
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Vistagen Therapeutics posts Q2 loss of $0.53 per share

* Vistagen therapeutics reports second fiscal quarter 2018 financial results and provides business update

10 Nov 2017

BRIEF-Vistagen Therapeutics receives European patent for AV-101 for treatment of depression

* Vistagen Therapeutics receives European patent for AV-101 for treatment of depression Source text for Eikon: Further company coverage:

06 Nov 2017

BRIEF-Vistagen gets FDA authorization to initiate phase 2 study for major depressive disorder

* Vistagen announces fda authorization to initiate phase 2 study of av-101 for major depressive disorder Source text for Eikon: Further company coverage:

26 Oct 2017

BRIEF-VistaGen Therapeutics files for offering of up to $23 mln of common stock

* VistaGen Therapeutics Inc files for offering of up to $23 million of common stock – SEC filing‍​ Source text: [http://bit.ly/2zkDNCU] Further company coverage:

19 Oct 2017

BRIEF-Vistagen receives notice of allowance from U.S. Patent And Trademark Office

* Vistagen receives notice of allowance from U.S. Patent and Trademark office for U.S. Patent regarding methods of production for av-101 Source text for Eikon: Further company coverage:

28 Sep 2017

BRIEF-Vistagen to buy up to 1.9 mln shares of common stock at $1.75 per share

* Vistagen announces pricing of underwritten offering of common stock and warrants to purchase common stock

31 Aug 2017

BRIEF-Vistagen Therapeutics appoints Dr. Mark Wallace to clinical advisory board

* Vistagen Therapeutics appoints Dr. Mark Wallace to clinical advisory board to advance AV-101 as a potential non-opioid treatment for neuropathic pain Source text for Eikon: Further company coverage:

10 Jul 2017

Earnings vs. Estimates